<DOC>
	<DOCNO>NCT00408239</DOCNO>
	<brief_summary>Evaluate safety tolerability escalate oral dos YM150 patient undergo elective primary total knee replacement surgery</brief_summary>
	<brief_title>Factor Xa Inhibitor Prevention Venous Thromboembolism Patients Undergoing Elective Total Knee Replacement</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<criteria>Scheduled elective primary total knee replacement surgery Legal minimum age requirement ( countryspecific ) Written informed consent obtain Documented history consider increase risk venous thromboembolism Subjects consider increase risk bleeding : Known hemorrhagic disorder and/or coagulation disorder Thrombocytopenia Clinically important bleeding occur within 3 month prior screen visit Acute bacterial endocarditis Severe hypertension Retinopathy Concomitant use anticoagulant / antiplatelet agent ( include homeopathic drug ) and/or anticipate postoperative need reason prevention DVT study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Factor Xa inhibitor</keyword>
	<keyword>Thromboembolism</keyword>
	<keyword>Arthroplasty</keyword>
	<keyword>Knee Replacement</keyword>
	<keyword>Prevention Control</keyword>
</DOC>